SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Jonuleit, T. Articles by Aulitzky, W. E. Search for Related Content PubMed PubMed Citation Articles by Jonuleit, T. Articles by Aulitzky, W. E. Related Collections Neoplasia Cell Cycle Oncogenes and Tumor Suppressors Signal Transduction Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 September 2000, Vol. 96, No. 5, pp. 1933-1939 NEOPLASIA Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines Tarja Jonuleit, Heiko van der Kuip, Cornelius Miething, Heike Michels, Michael Hallek, Justus Duyster, and Walter E. Aulitzky From the Dr Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart, Germany; 2nd Department of Internal Medicine, Oncology Hematology, Robert Bosch Hospital, Stuttgart, Germany; Department of Internal Medicine III. Technical University of Munich; and Medizinische Klinik, Klinikum Innenstadt, University of Munich, Germany. Chronic myeloid leukemia (CML) is a malignant stem cell disease characterized by an expansion of myeloid progenitor cells expressing the constitutively activated Bcr-Abl kinase. This oncogenic event causes a deregulation of apoptosis and cell cycle progression. Although the molecular mechanisms protecting from apoptosis in CML cells are well characterized, the cell cycle regulatory event is poorly understood. An inhibitor of the cyclin-dependent kinases, p27, plays a central role in the regulation of growth factor dependent proliferation of hematopoietic cells. Therefore, we have analyzed the influence of Bcr-Abl in the regulation of p27 expression in various hematopoietic cell systems. An active Bcr-Abl kinase causes down-regulation of p27 expression in murine Ba/F3 cells and human M07 cells. Bcr-Abl blocks up-regulation of p27 after growth factor withdrawal and serum reduction. In addition, p27 induction by transforming growth factor-beta (TGF-) is completely blocked in Bcr-Abl positive M07/p210 cells. This deregulation is directly mediated by the activity of the Bcr-Abl kinase. A Bcr-Abl kinase inhibitor completely abolishes p27 down-regulation by Bcr-Abl in both Ba/F3 cells transfected either with a constitutively active Bcr-Abl or with a temperature sensitive mutant. The down-regulation of p27 by Bcr-Abl depends on proteasomal degradation and can be blocked by lactacystin. Overexpression of wild-type p27 partially antagonizes Bcr-Abl-induced proliferation in Ba/F3 cells. We conclude that Bcr-Abl promotes cell cycle progression and activation of cyclin-dependent kinases by interfering with the regulation of the cell cycle inhibitory protein p27. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Agarwal, T. G. P. Bumm, A. S. Corbin, T. O'Hare, M. Loriaux, J. VanDyke, S. G. Willis, J. Deininger, K. I. Nakayama, B. J. Druker, et al. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease Blood, September 1, 2008; 112(5): 1960 - 1970. [Abstract] [Full Text] [PDF] J. G. Harb, B. I. Chyla, and C. S. Huettner Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis Blood, April 1, 2008; 111(7): 3760 - 3769. [Abstract] [Full Text] [PDF] S.-J. Zhang, L.-Y. Ma, Q.-H. Huang, G. Li, B.-W. Gu, X.-D. Gao, J.-Y. Shi, Y.-Y. Wang, L. Gao, X. Cai, et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia PNAS, February 12, 2008; 105(6): 2076 - 2081. [Abstract] [Full Text] [PDF] G. Ferretti, E. Bria, D. Giannarelli, P. Carlini, A. Felici, M. Mandala, P. Papaldo, A. Fabi, M. Ciccarese, F. Cuppone, et al. Is Recurrent Venous Thromboembolism After Therapy Reduced by Low-Molecular-Weight Heparin Compared With Oral Anticoagulants? Chest, December 1, 2006; 130(6): 1808 - 1816. [Abstract] [Full Text] [PDF] W. Fiskus, M. Pranpat, M. Balasis, P. Bali, V. Estrella, S. Kumaraswamy, R. Rao, K. Rocha, B. Herger, F. Lee, et al. Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate-Sensitive or Imatinib Mesylate-Resistant Chronic Myelogenous Leukemia Cells. Clin. Cancer Res., October 1, 2006; 12(19): 5869 - 5878. [Abstract] [Full Text] [PDF] W. Fiskus, M. Pranpat, P. Bali, M. Balasis, S. Kumaraswamy, S. Boyapalle, K. Rocha, J. Wu, F. Giles, P. W. Manley, et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells Blood, July 15, 2006; 108(2): 645 - 652. [Abstract] [Full Text] [PDF] E. J. Andreu, E. Lledo, E. Poch, C. Ivorra, M. P. Albero, J. A. Martinez-Climent, C. Montiel-Duarte, J. Rifon, J. Perez-Calvo, C. Arbona, et al. BCR-ABL Induces the Expression of Skp2 through the PI3K Pathway to Promote p27Kip1 Degradation and Proliferation of Chronic Myelogenous Leukemia Cells Cancer Res., April 15, 2005; 65(8): 3264 - 3272. [Abstract] [Full Text] [PDF] J.-F. Geay, D. Buet, Y. Zhang, A. Foudi, P. Jarrier, M. Berthebaud, A. G. Turhan, W. Vainchenker, and F. Louache p210BCR-ABL inhibits SDF-1 Chemotactic Response via Alteration of CXCR4 Signaling and Down-regulation of CXCR4 Expression Cancer Res., April 1, 2005; 65(7): 2676 - 2683. [Abstract] [Full Text] [PDF] K. L. Kathrein, R. Lorenz, A. M. Innes, E. Griffiths, and S. Winandy Ikaros Induces Quiescence and T-Cell Differentiation in a Leukemia Cell Line Mol. Cell. Biol., March 1, 2005; 25(5): 1645 - 1654. [Abstract] [Full Text] [PDF] K. Tomoda, J.-y. Kato, E. Tatsumi, T. Takahashi, Y. Matsuo, and N. Yoneda-Kato The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression Blood, January 15, 2005; 105(2): 775 - 783. [Abstract] [Full Text] [PDF] B. Calabretta and D. Perrotti The biology of CML blast crisis Blood, June 1, 2004; 103(11): 4010 - 4022. [Abstract] [Full Text] [PDF] L. Wohlbold, H. van der Kuip, C. Miething, H.-P. Vornlocher, C. Knabbe, J. Duyster, and W. E. Aulitzky Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571) Blood, September 15, 2003; 102(6): 2236 - 2239. [Abstract] [Full Text] [PDF] R. Nimmanapalli, L. Fuino, P. Bali, M. Gasparetto, M. Glozak, J. Tao, L. Moscinski, C. Smith, J. Wu, R. Jove, et al. Histone Deacetylase Inhibitor LAQ824 Both Lowers Expression and Promotes Proteasomal Degradation of Bcr-Abl and Induces Apoptosis of Imatinib Mesylate-sensitive or -refractory Chronic Myelogenous Leukemia-Blast Crisis Cells Cancer Res., August 15, 2003; 63(16): 5126 - 5135. [Abstract] [Full Text] [PDF] X.-F. Le, F.-X. Claret, A. Lammayot, L. Tian, D. Deshpande, R. LaPushin, A. M. Tari, and R. C. Bast Jr. The Role of Cyclin-dependent Kinase Inhibitor p27Kip1 in Anti-HER2 Antibody-induced G1 Cell Cycle Arrest and Tumor Growth Inhibition J. Biol. Chem., June 20, 2003; 278(26): 23441 - 23450. [Abstract] [Full Text] [PDF] N. Komatsu, T. Watanabe, M. Uchida, M. Mori, K. Kirito, S. Kikuchi, Q. Liu, T. Tauchi, K. Miyazawa, H. Endo, et al. A Member of Forkhead Transcription Factor FKHRL1 Is a Downstream Effector of STI571-induced Cell Cycle Arrest in BCR-ABL-expressing Cells J. Biol. Chem., February 14, 2003; 278(8): 6411 - 6419. [Abstract] [Full Text] [PDF] J. C. H. Donovan, J. M. Rothenstein, and J. M. Slingerland Non-malignant and Tumor-derived Cells Differ in Their Requirement for p27Kip1 in Transforming Growth Factor-beta -mediated G1 Arrest J. Biol. Chem., October 25, 2002; 277(44): 41686 - 41692. [Abstract] [Full Text] [PDF] M. S. Holtz, M. L. Slovak, F. Zhang, C. L. Sawyers, S. J. Forman, and R. Bhatia Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation Blood, May 15, 2002; 99(10): 3792 - 3800. [Abstract] [Full Text] [PDF] A. W. Goetz, H. van der Kuip, R. Maya, M. Oren, and W. E. Aulitzky Requirement for Mdm2 in the Survival Effects of Bcr-Abl and Interleukin 3 in Hematopoietic Cells Cancer Res., October 1, 2001; 61(20): 7635 - 7641. [Abstract] [Full Text] [PDF] H. van der Kuip, A. W. Goetz, C. Miething, J. Duyster, and W. E. Aulitzky Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis Blood, September 1, 2001; 98(5): 1532 - 1541. [Abstract] [Full Text] [PDF] H. Jonuleit, E. Schmitt, M. Stassen, A. Tuettenberg, J. Knop, and A. H. Enk Identification and Functional Characterization of Human CD4+CD25+ T Cells with Regulatory Properties Isolated from Peripheral Blood J. Exp. Med., June 4, 2001; 193(11): 1285 - 1294. [Abstract] [Full Text] [PDF] Y. Parada, L. Banerji, J. Glassford, N. C. Lea, M. Collado, C. Rivas, J. L. Lewis, M. Y. Gordon, N. S. B. Thomas, and E. W.-F. Lam BCR-ABL and Interleukin 3 Promote Haematopoietic Cell Proliferation and Survival through Modulation of Cyclin D2 and p27Kip1 Expression J. Biol. Chem., June 22, 2001; 276(26): 23572 - 23580. [Abstract] [Full Text] [PDF]

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020